Health and Pharma

The UK has initiated the first human trial of an innovative mRNA-based lung cancer vaccine, BioNTech's BNT116, designed to enhance the body's ability to recognize and attack NSCLC cells. https://lnkd.in/dk5csrqZ

Skye Bioscience Inc. has started screening #patients for a Phase 2 clinical trial (#CBeyond™) of its novel peripheral #CB1inhibitor, #nimacimab, a negative allosteric modulating antibody targeting #obesity.  This study not only tests nimacimab's effectiveness and safety in conjunction with the #GLP1 receptor agonist #Wegovy, but also marks a significant stride beyond traditional incretin-based therapies. #WeightLoss https://lnkd.in/dxGZZ52f

Phanes Therapeutics, Inc. has announced that its investigational the novel #cancer #drug, #PT217, has received #FDA Orphan Drug Designation for treating #neuroendocrine #carcinoma (NEC). PT217, which targets DLL3 and CD47, offers new hope for #NEC patients, typically found in the lungs and other organs. https://lnkd.in/dr6DfsbV

In this exclusive interview, we have a special guest, Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma Inc. (Nasdaq: LTRN), to discuss 'Breakthrough in #LungCancer Treatment for Never Smokers' including the novel #AI-assisted drug candidate #LP300. We'll dive into the promising results of the #HARMONIC Phase 2 trial, focusing on LP-300 and its significant implications for treating #lung #cancer. Additionally, we’ll explore the transformative role of #artificialintelligence in #drugdiscovery, particularly how it's reshaping #clinicaltrials and treatment strategies. https://lnkd.in/dVbpWEmm

The Phase 2 #HARMONIC™ trial, leveraging the #AI-assisted RADR® platform, demonstrates promising outcomes for #LP300 in treating non-small cell #lungcancer (#NSCLC) in never smokers, with an 86% clinical benefit rate. https://lnkd.in/dMJTZ7pC

In a recent exclusive interview with #ONCOLife, Dr. Tara Frenkl, Bayer's Head of Global Medical Strategy, shared profound insights into the company's strategic focus on #prostatecancer. Dr. Frenkl emphasized Bayer Oncology's commitment to not only extending survival rates but also enhancing the quality of life for #cancer patients through innovative therapies. #Oncology #CancerTreatment Read the article, here: #ASCO2024 Special Edition https://lnkd.in/gu9tW4XW

#FDA has approved #Neffy, the first #nasalspray containing #epinephrine for treating severe #allergic reactions, including #anaphylaxis. Clinical trials confirm its efficacy, showing that Neffy offers a needle-free alternative, which may increase its usage among those who fear injections. Results demonstrate that it is comparable to injectable epinephrine. #Allergy https://lnkd.in/dWjkPHQP

Surgical Planning Associates (SPA) announced that its groundbreaking #MixedReality #3D guidance system, #HipInsight has received #FDA 510(k) clearance for #hiparthroplasty. This innovative technology marks a milestone in #surgical procedures, offering unprecedented precision and customization in hipsurgery. It allows #surgeons to maintain their focus on the patient without the frequent need to consult external monitors or imagery.  https://lnkd.in/dJtAwBmA

In this exclusive interview, we have a special guest, Dr. Catherine Duggan, CEO of the International Pharmaceutical Federation (FIP) Pharmaceutical Federation, to discuss "The Role of #Pharmacists in the Fight Against #LiverDisease." We will explore various dimensions of this critical issue, as #liver diseases are one of the major topics on the global #health agenda. #Pharmaceutical https://lnkd.in/du2pb_Xu

Merck has discontinued its #KeyVibe008 trial for extensive-stage small cell #lungcancer due to unmet primary endpoints and increased adverse events. The trial evaluated a fixed-dose combination of #vibostolimab and #pembrolizumab (#KEYTRUDA). #lung #cancer https://lnkd.in/dQ5CdW99